Press releases

5 February, 2015

Regulatory

OnCore Biopharma and Tekmira Pharmaceuticals files for merger – releases further details about license agreement with NeuroVive

NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, is able to present further details regarding the previously communicated exclusive, worldwide licensing agreement with OnCore Biop ...

19 January, 2015

Regulatory

Merger between OnCore and Tekmira includes development of NVP018 for the treatment of Hepatitis B

US biotechnology company OnCore Biopharma, Inc. (OnCore), which has licensed NeuroVive's drug candidate NVP018 for the treatment of chronic Hepatitis B virus infection (HBV), has agreed to merge with ...

12 January, 2015

Regulatory

Annual General Meeting brought forward to March 30 2015

The Board of NeuroVive Pharmaceutical AB (publ) has decided to bring forward the Annual General Meeting 2015 to Monday 30 March, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden to ...

2 December, 2014

Regulatory

NeuroVive and Skåne University Hospital initiate collaboration on clinical phase II study on kidney protection during heart surgery

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has initiated a collaboration with Skåne University Hospital to complete a clinical phase II study on the evaluation of the comp ...

29 October, 2014

Regulatory

Annual General Meeting 2015 and information about members appointed to the Nomination Committee

The Annual General Meeting in NeuroVive Pharmaceutical AB (publ) will be held on Wednesday 29 April, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.

11 September, 2014

Addendum: OnCore License

At the request of NASDAQ OMX Stockholm, the Company provides the following information regarding the license agreement referred to in the press release dated September 9, 2014.

9 September, 2014

Regulatory

NeuroVive signs USD 150 m agreement with OnCore BioPharma for the outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection

NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, has signed an exclusive global outlicensing agreement with the US biotechnology company OnCore BioPharma, Inc. related to the deve ...

14 August, 2014

Regulatory

Enrollment to phase II study on NeuroSTAT® continues

Enrollment to the ongoing clinical phase IIa study with NeuroVive's drug candidate NeuroSTAT® for treating patients with severe traumatic brain injury (TBI) is continuing, and another two patients hav ...

10 June, 2014

Regulatory

NeuroVive’s research into energy regulation wins award at international research symposium

NeuroVive, a leading mitochondrial medicine company, participated in the international research symposium Mitochondrial Medicine 2014 held in Pittsburgh, USA, on 4-7 June. NeuroVive presented research ...

4 June, 2014

Regulatory

NeuroVive signs new agreement with Hospices Civils de Lyon

NeuroVive is extending its collaboration with Hospices Civils de Lyon (HCL) and Professor Ovize, which broadens the scope of NeuroVive's cardiovascular business area and creates the right conditions f ...

9 May, 2014

Regulatory

Report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) today, 9 May 2014. A summary of the resolutions follows. All decisions received the required majorities.

17 April, 2014

Regulatory

NeuroVive presents medical breakthrough in cellular energy regulation

NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level. Based on the UK company Selcia Ltd's medical chemist ...